Business Wire

  1. Alnylam Forms Collaboration With Max Planck Institute To Investigate Biological Mechanisms For Cellular Uptake of RNAi Therapeutics 8/11/2008
    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced it has formed an exclusive research agreement with the Max Planck Institute of Molecular Cell Biology and Genetics in Dresden, Germany.
  2. Helicos And Uppsala University Collaborate To Study Genome Structure And Its Effects On Gene Expression Utilizing True Single Molecule Sequencing Technology 8/5/2008
    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Helicos BioSciences Corporation (NASDAQ:HLCS) today announced a scientific collaboration with a respected genomics research group at Sweden’s Uppsala University aimed at gaining new insights into how genome structure plays a key role in the ways genes are regulated within cells
  3. Alnylam Consolidates Intellectual Property For RNA Activation (RNAa), A New Biological Discovery For Activation Of Gene Expression 8/4/2008
    Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that it has consolidated the key intellectual property (IP) for RNA activation (RNAa), creating a dominant IP position in this new area of biology
  4. Invitrogen Licenses Stem Cell Line From Buck Institute 7/30/2008
    Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for research, production and diagnostics, has licensed an engineered stem cell line from the Buck Institute for Age Research
  5. Increased Sample Throughput On Applied Biosystems Genomic Analysis Platform Simplifies Study Of Small RNAs 7/29/2008
    Research related to the roles that small non-coding RNA molecules play in living cells is one of the fastest growing areas in biology
  6. Invitrogen To Integrate Brendan Technologies' Advanced Analytical Software Into Protein Analysis Solutions 7/11/2008
    Invitrogen Corporation (NASDAQ:IVGN), a leading provider of essential life sciences technologies for research, production and diagnostics, announced today it has entered into an exclusive agreement with Brendan Technologies (OTCBB:BDTE) to customize its StatLIA® assay analysis software to facilitate the analysis of protein samples
  7. xCELLigence - Online-Measurement Of Cell Activities Without Labelling 7/7/2008
    We are pleased to announce the launch of the xCELLigence System, a cell-based assay system that represents the perfect integration of micro electronics and cell biology
  8. PerkinElmer Establishes ViaCord Research Institute To Further Cord Blood Stem Cell Advancements 7/3/2008
    PerkinElmer, Inc., a global leader in Health Sciences and Photonics, today announced the creation of the ViaCord Research Institute™ (VRI™) aimed at investigating new potential future uses of umbilical cord blood-derived stem cells